Skip to search formSkip to main contentSkip to account menu

response to fenofibrate

Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Lipid changes due to fenofibrate treatment are not associated with changes in DNA methylation patterns in the GOLDN study
Fenofibrate lowers triglycerides (TG) and raises high density lipoprotein cholesterol (HDLc) in dyslipidemic individuals. Several… 
Highly Cited
2012
Highly Cited
2012
A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network
Objective Despite the evidence in support of the anti-inflammatory and triglyceride-lowering effects of fenofibrate, little is… 
2012
2012
The PPAR Alpha gene is associated with triglyceride, low-density cholesterol, and inflammation marker response to fenofibrate intervention: The GOLDN Study
As a peroxisome proliferator-activated receptor alpha (PPARα) agonist, fenofibrate favorably modulates dyslipidemia and… 
2012
2012
Variants Identified in a GWAS Meta-Analysis for Blood Lipids Are Associated with the Lipid Response to Fenofibrate
A recent large-scale meta-analysis of genome-wide studies has identified 95 loci, 59 of them novel, as statistically significant… 
2012
2012
Clustering by Plasma Lipoprotein Profile Reveals Two Distinct Subgroups with Positive Lipid Response to Fenofibrate Therapy
Fibrates lower triglycerides and raise HDL cholesterol in dyslipidemic patients, but show heterogeneous treatment response. We… 
2010
2010
Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study[S]
Hypertriglyceridemia, defined as a triglyceride measurement > 150 mg/dl, occurs in up to 34% of adults. Fenofibrate is a commonly… 
2010
2010
Apolipoprotein E Polymorphisms and Postprandial Triglyceridemia Before and After Fenofibrate Treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study
Background—Although much is known about the effect of Apolipoprotein E (APOE) alleles on fasting lipid concentrations, less is… 
2010
2010
Heterogeneous Postprandial Lipoprotein Responses in the Metabolic Syndrome, and Response to Fenofibrate Therapy
BackgroundHypertriglyceridemia subjects with metabolic syndrome exhibit variable postprandial triglyceride responses. We… 
2008
2008
The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment
Metabolic response to the triglyceride (TG)-lowering drug, fenofibrate, is shaped by interactions between genetic and… 
Highly Cited
2007
Highly Cited
2007
Fenofibrate Effect on Triglyceride and Postprandial Response of Apolipoprotein A5 Variants: The GOLDN Study
Objective—Apolipoprotein A5 (APOA5) is a key determinant of plasma triglyceride (TG) concentrations. Genetic variation at the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)